News >

Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL

Danielle Ternyila
Published: Monday, Dec 23, 2019

blood cellsDInduction therapy with R-CHOP followed by maintenance rituximab (Rituxan) continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha (IFN) maintenance in older patients with mantle cell lymphoma (MCL), according to updating findings from the randomized, open-label phase III European MCL Elderly trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication